GLP-1 (Glucagon-Like Peptide-1) Is Physiologically Relevant for Chylomicron Secretion Beyond Its Known Pharmacological Role

Emerging Role of Lymphatics in the Regulation of Intestinal Lipid Mobilization

(2020) Changting Xiao et al.   Frontiers in Physiology

Intestinal basolateral lipid substrate transport (BLST) is linked to chylomicron secretion and is regulated by apoC-III.

(2019) Diana Li et al.   JOURNAL OF LIPID RESEARCH

Glucose and GLP-2 (Glucagon-Like Peptide-2) Mobilize Intestinal Triglyceride by Distinct Mechanisms

(2019) Priska Stahel et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

ATGL/CGI-58-Dependent Hydrolysis of a Lipid Storage Pool in Murine Enterocytes

(2019) Melanie Korbelius et al.   Cell Reports

An overview of GLP-1 agonists and recent cardiovascular outcomes trials

(2019) Kelsey H Sheahan et al.   POSTGRADUATE MEDICAL JOURNAL

Intestinal lymph as a readout of meal-induced GLP-1 release in an unrestrained rat model

(2018) Nino Jejelava et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

The endogenous preproglucagon system is not essential for gut growth homeostasis in mice

(2017) Pernille Wismann et al.   Molecular Metabolism

New Insights into the Regulation of Chylomicron Production

(2015) Satya Dash et al.   Annual Review of Nutrition

Central Nervous System Regulation of Intestinal Lipoprotein Metabolism by Glucagon-Like Peptide-1 via a Brain-Gut Axis

(2015) S. Farr et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R

(2015) Bernardo Yusta et al.   DIABETES

Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease

(2014) Robert S. Rosenson et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Triglycerides and cardiovascular disease

(2014) Børge G Nordestgaard et al.   LANCET

Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial

(2013) K. Hermansen et al.   DIABETES OBESITY & METABOLISM

Exenatide, a Glucagon-like Peptide-1 Receptor Agonist, Acutely Inhibits Intestinal Lipoprotein Production in Healthy Humans

(2012) Changting Xiao et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

GLP-1 and GLP-2 as Yin and Yang of Intestinal Lipoprotein Production: Evidence for Predominance of GLP-2-Stimulated Postprandial Lipemia in Normal and Insulin-Resistant States

(2012) G. J. Hein et al.   DIABETES

Large-scale association analysis identifies new risk loci for coronary artery disease

(2012) Panos Deloukas et al.   NATURE GENETICS

The Biogenesis of Chylomicrons

(2010) Charles M. Mansbach et al.   Annual Review of Physiology

One-year treatment with exenatide vs. Insulin Glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress

(2010) Mathijs C. Bunck et al.   ATHEROSCLEROSIS

The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice

(2009) J. Hsieh et al.   DIABETOLOGIA

Evidence that Intestinal Glucagon-Like Peptide-1 Plays a Physiological Role in Satiety

(2008) Diana L. Williams et al.   ENDOCRINOLOGY